In conclusion, the frequency of RUNX2 gain and elevated RUNX2 in osteosarcoma patient specimens as well as its documented functions lends to its possible value as a predictive factor and as a therapeutic target. The gene discussed is RUNX2; the disease is osteosarcoma.